Wagner N D, Quinones V W
Barnes Jewish Hospital, St. Louis, MO, USA.
Oncol Nurs Forum. 1998 Jul;25(6):1049-55; quiz 1056-7.
PURPOSE/OBJECTIVES: To provide a comprehensive understanding of allogeneic peripheral blood stem cell transplantation (PBSCT), the new modality for treating advanced hematologic malignancies.
Journal articles/abstracts, published literature, clinical experience.
Growth factor mobilization and apheresis is well tolerated by donors and supplies adequate numbers of stem cells for engraftment. Patients engraft sooner using PBSCT compared to bone marrow transplant (BMT).
Allogeneic PBSCT is a safe alternative to BMT and has distinct advantages for donors and recipients. Faster engraftment results in fewer transfusions, shorter hospitalization, and decreased cost. Future research to determine if long-term side effects from growth factors will negatively affect donors is essential. Data regarding durability of hematopoiesis and incidence of graft versus host disease warrant further analysis.
Care for patients is similar to that of standard BMT; however, care for donors is unique. Shorter hospitalization requires nurses to alter content and timing of patient education and preparation for discharge.
目的/目标：全面了解异基因外周血干细胞移植（PBSCT），这一治疗晚期血液系统恶性肿瘤的新方法。
期刊文章/摘要、已发表文献、临床经验。
供者对生长因子动员和单采术耐受性良好，且能提供足够数量的干细胞用于植入。与骨髓移植（BMT）相比，患者接受PBSCT后造血重建更快。
异基因PBSCT是BMT的一种安全替代方法，对供者和受者都有明显优势。更快的造血重建导致输血次数减少、住院时间缩短和成本降低。确定生长因子的长期副作用是否会对供者产生负面影响的未来研究至关重要。关于造血功能持久性和移植物抗宿主病发生率的数据值得进一步分析。
对患者的护理与标准BMT相似；然而，对供者的护理是独特的。住院时间缩短要求护士改变患者教育的内容和时机以及出院准备工作。
